Additional file 1 of Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors

Institutions

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.28559868
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additional file 1 of Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors

Figshare
HER2/EGFR in Cancer Research
article

Additional file 1 of Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors

article en

Abstract

No abstract available for this paper.
Figshare
Chinese Academy of Sciences (CN), Peking University (CN), Peking University Third Hospital (CN), University of Chinese Academy of Sciences (CN), Beihang University (CN), Guangzhou Medical University (CN)
Good health and well-being
Openalex Percentile: Top 42%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Additional file 1 of Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors · Figshare (2025) | TGRS Research Map | TGRS